Mucositis remains an important problem following BMT and may delay discharge from hospital. Patientcontrolled analgesia (PCA) systems have been reported to be of benefit in controlling BMT-associated mucositis. The present study comprised 65 patients (age range 16-68 years; 19 allografts, 29 peripheral blood stem cell autografts and 17 autologous bone marrow). Subjects were prospectively randomised to receive intravenous diamorphine for pain relief either by conventional continuous infusion (CI) or by PCA, using a Medex Walkman 440 delivery system. Each patient assessed his/her pain control and nausea daily by a visual analogue scale. Twenty-two patients did not require any diamorphine. Four patients required diamorphine for pain other than mucositis, and four patients failed PCA control. Of 35 assessable cases, no difference in pain control was noted between CI and PCA. However, PCA-controlled patients required significantly less diamorphine than CI controlled patients (mean, 131 ؎ 23 mg for PCA vs 296 ؎ 40 mg for CI; P = 0.001), and PCA required fewer days of diamorphine than CI (mean, 7.17 ؎ 0.66 days for PCA, 9.00 ؎ 0.65 days for CI; P = 0.03). Sideeffects were minimal and equivalent in the two arms. The findings suggest that PCA and CI offer equivalent control of the pain of BMT-associated mucositis, but PCA requires less total consumption and duration of diamorphine therapy.
phine in this way. Pain varies throughout the day, depending on, for example, physical activity, distractions or the sight and smell of food and drink. A constant continuous infusion rate cannot respond to these changes. Although the dose can be increased by attendant health care professionals, this can cause excessive drowsiness or nausea. Furthermore, decisions about decreases in dosage can be difficult, and may lead to symptoms of opiate withdrawal if carried out too rapidly, especially if a high dose has been given for long periods, and this may in turn delay the patient's discharge.
A system in which the patient has direct control over diamorphine delivery may therefore offer some advantages. Patient controlled analgesia (PCA) systems are activated by means of a hand-held device resulting in the intravenous or subcutaneous delivery of a small bolus of drug. At the same time a 'lock-out' is activated within the system preventing further dose delivery for a time interval which can be set by the doctor/nurse, thus minimising the risk of overdosage. PCA has been demonstrated to be a safe and effective method of administering opiate analgesics to patients postoperatively and during labour, [3] [4] [5] and for the control of pain associated with advanced cancer. 6 In two related studies from Seattle, PCA was reported as a safe method of administering morphine for the control of mucositis-associated pain. 7, 8 These studies were carried out before the widespread introduction of peripheral blood stem cell (PBSC) transplantation. PBSC recipients typically engraft more quickly than recipients of bone marrow, and control of mucositis may be proportionally more important than the blood count in determining timing of discharge from hospital.
In the present study, we examined whether earlier favourable reports on the use of PCA were applicable to a contemporary cohort of BMT recipients. We also examined PCA for the delivery of diamorphine, which is now more widely used than morphine for the control of mucositisassociated pain. We report that a PCA system for delivery of diamorphine controls mucositis pain as well as a continuous diamorphine infusion, with less diamorphine usage and duration of usage.
Patients and methods

Study population
The study was open for 30 months commencing in February 1995. At first, patients undergoing autologous transplantation of peripheral blood stem cells (PBSC) were excluded from the study, in case their duration and severity of mucositis was shorter because of more rapid haemopoietic recovery. However, PBSC recipients were included from June 1995 onward, as our initial experience showed that the severity of mucositis depends on the conditioning regimen rather than the type of transplant. A total of 81 patients were eligible for the study, but entry was not offered to four patients (two because of language problems affecting informed consent, one because of previous psychiatric problems, and one because her lymphoma directly involved the oropharynx and palate). The remaining 77 patients were invited to enter the present study after an explanation of its aims, and 65 did so, giving informed written consent.
The demographic and transplant details of these 65 cases are summarised in Table 1 . Patient ages ranged from 16 to 68 (median 39 years), and the group contained 41 males and 24 females. Nineteen of the transplants were allografts (six using volunteer unrelated donors (VUD)), and 46 were autografts (29 using peripheral blood-derived stem cells). All patients received the following antimicrobial prophylaxis from commencement of conditioning therapy until the PB neutrophil count reached at least 0.5 ϫ 10 9 /l on two consecutive occasions: amphotericin lozenges 10 mg, nystatin oral suspension 100 000 units, 0.2% chlorhexidine mouthwash 10 ml and oral acyclovir 200 mg (autografts) or 400 mg (allografts) orally each four times daily, and oral ciprofloxacin 500 mg and colistin 1.5 megaunits each, twice daily. No azole antifungal prophylaxis was used.
Study design
The study was a prospective randomised comparison of conventional continuous diamorphine infusion vs PCA. Ran- Table 1 Details of patients entered into the study and on those yielding assessable data CML = chronic myeloid leukaemia; cyclo = cyclophosphamide; TBI = total body irradiation; HDM = high-dose melphalan.
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domisation was by serial sealed envelopes containing computer-generated random treatment allocations to one of the following regimens: (1) Conventional continuous intravenous diamorphine infusion: Pain control was discussed with the patient at least once daily. When simple measures for mucositis control (eg difflam mouthwash, paracetamol gargles) were no longer effective, and/or when the patient wished, a diamorphine infusion was commenced at a dose of 48 mg in 7.8 ml water for injection, using a continuous infusion pump (Graseby Medical Ltd, Watford, UK), set at 24 mm/day (ie 24 mg diamorphine per 24 h). Patients were then assessed 4 hourly; if still in discomfort and wishing dose escalation yet without significant opiate side-effects, the dose was escalated by increments of 12 mg/24 h at each step.
A maximum of three increments was permitted per 24-h period. In this way, the maximum permitted continuous infusion rate of 96 mg/24 h could theoretically be reached within 48 h of commencing the infusion. When patients reported two consecutive decreases in pain 4 h apart, the dose rate was decreased by 12 mg/24 h. Subsequent increases in dose rate were permitted either if pain control worsened or if symptoms of opiate withdrawal emerged.
(2) Patient controlled analgesia: Syringes were prepared under sterile conditions, containing 200 mg diamorphine in 50 ml water for injections (ie 4 mg/ml). A Medex Walkman 440 (Haslingden, UK) was used. This was initially set to deliver a bolus of 0.8 mg of diamorphine intravenously, with a lock-out time of 10 min, but also set to deliver a maximum of 2 mg/h. At the 4 hourly assessment points, the bolus size could be increased to 1.2 mg, with a maximum hourly rate of 4 mg (ie 96 mg per 24 h). Further increases in bolus size or frequency of delivery were not permitted. Since PCA patients directly determine their own diamorphine dosage, no rules regarding dosage decrease were required.
In order to promote rest and sleep at night, between 11 pm and 7 am a background infusion function of the Walkman 440 was used. The infusion rate was defined as the average hourly consumption of diamorphine over the preceding 16 h. Additional PCA delivery was permitted, up to the maximum rate of 4 mg/h.
In each arm, patients requiring greater doses than 96 mg/day were deemed off-study. The study was approved by the Liverpool Research Ethics Committee.
The following assessments were carried out for all patients: (1) Pain control: This was assessed by the patient each afternoon, using a visual analogue scale. 9 This comprised asking the patient to mark his/her pain score along a non-graduated 10 cm horizontal line. The score was defined as the distance from the origin to the patient's mark, rounded up or down to the nearest whole centimetre.
(2) Side-effects: At the same time as the pain control assessment, the patient was asked to rate a nausea score, using a similar 10 cm visual analogue scale. Respiratory and pulse rates and blood pressure were recorded 4-hourly, according to routine practice.
(3) Diamorphine usage (day of commencement post-BMT, daily dose, total dose, and number of days of usage). Table 1 gives the distribution of all 65 patients between the continuous infusion (CI) and PCA arms. Twenty-two patients did not require diamorphine at all. A total of 43 patients were therefore treated with their allocated diamorphine schedule (20 patients by CI and 23 by PCA); their clinical data is also given in Table 1 . The allograft:autograft ratio was greater in the group allocated PCA, and this was especially true in patients who received treatment. This is reflected in the higher number of patients conditioned with cyclophosphamide and total body irradiation (TBI) in the PCA group. The distribution of underlying diagnosis is similar between the two groups.
Results
About three-quarters of the patients conditioned with cyclophosphamide/TBI or with high-dose melphalan developed mucositis severe enough to require diamorphine. In contrast, only half of patients conditioned with BEAM (BCNU, etoposide, Ara-C and melphalan) required diamorphine; lymphoma patients therefore account for the majority of patients who did not require diamorphine.
Four patients required diamorphine for pain other than mucositis (three due to abdominal pain, and one because of a central line-associated thrombosis). Four patients failed an attempt to receive PCA (one case because the patient decided he would prefer a continuous infusion; two because of previous favourable experience with a continuous infusion; and one because of a technical failure with the PCA delivery apparatus). Each of these eight cases was taken off study. The following data are therefore from 35 assessable cases (17 CI; 18 PCA). None of these cases required any additional analgesia. 
Comparison of CI and PCA for pain control
Patients in each arm of the study commenced diamorphine at comparable times post-BMT (CI at a mean of 6.00 Ϯ 0.51 days, PCA at 6.94 Ϯ 0.72 days; P = 0.57). Figure 1 gives mean pain scores for the 35 assessable cases. Day 1 is defined as the day on which diamorphine commenced. No difference is seen between patients controlled with CI or PCA. Among recipients of autologous grafts, no difference between CI and PCA was seen. PBSC recipients required similar amounts and duration of diamorphine to autologous bone marrow recipients. No obvious difference was seen between the two methods of pain control for allogenic recipients, though the number of cases is small (data not shown). Figure 2 gives the diamorphine requirements for the two analgesia schedules. The mean (Ϯ standard error) total dose in the CI and PCA treated patients was 296.1 Ϯ 39.8 and 130.9 Ϯ 23.2 mg, respectively, and this difference achieved statistical significance using the Mann-Whitney test (P = 0.001). Similar differences in consumption were apparent among autologous recipients alone. CI-treated patients required a mean (Ϯ standard error) of 9.00 Ϯ 0.653 days treatment, while PCA-treated patients required 7.17 Ϯ 0.663 days (P = 0.036 by the Mann-Whitney test). Figure 3 shows the mean nausea scores. Day 1 is defined as the day on which diamorphine was commenced. No difference was seen between the CI and PCA-treated patients. No increase in nausea score was seen as the diamorphine dose was altered during the period of treatment. No difference in the respiratory or pulse rates or blood pressure recordings were seen either between the two treatment arms, nor during the varying doses of diamorphine during treatment.
Side-effect profile
Discussion
The present findings suggest that patient-controlled analgesia offers equivalent control of the pain of BMT-associated mucositis, when compared to the conventional continuous diamorphine infusion. However, significantly less diamorphine was used in the patients controlled with PCA, and diamorphine was required for on average 2 fewer days. Significant nausea and respiratory depression were not seen in any patient in either study arm. Our findings are therefore in agreement with those of Hill and colleagues. 7, 8 The pattern of diamorphine delivery in the PCA-treated patients has implications for the routine administration of continuously infused diamorphine in the control of BMTassociated mucositis. The algorithm used for the present CI arm was derived from our practice immediately prior to the commencement of the study. Many patients would delay commencing diamorphine too long, then rapidly need to escalate the dose after commencement as pain control was initially inadequate. In the present study, no patient in the CI arm needed more than two dose escalations within a single 24-hour period (a maximum of three escalations was permitted), yet many patients required several escalations over the first 48 h, suggesting that pain control over this interval was less than optimal. However, when patients are given more freedom to determine their own dose directly, the same level of pain control may be achieved with less consumption of diamorphine. This suggests that a proportion of patients may be inadvertently overtreated if using continuous diamorphine infusions. This might lead to later psychological difficulties in diamorphine withdrawal after the mucositis subsides.
Diamorphine is not an expensive drug, in comparison with the chemotherapy and antimicrobial drugs used in BMT, and the staff time required for its administration is not great. Considerable capital outlay is required for the purchase of the apparatus for PCA delivery. Therefore, although diamorphine usage is less in the PCA arm, the adoption of PCA for all BMT patients might paradoxically increase the overall cost of BMT. However, the duration of diamorphine treatment was less in the PCA-treated patients. In BMT recipients who engraft rapidly (eg PBSC recipients), mucositis rather than cytopenia may be the limiting factor determining discharge from hospital. It is interesting to speculate that PCA might therefore hasten the discharge of PBSC recipients, and thus prove cost-effective. The present study was not designed to examine the factors that determine discharge following BMT, and it is therefore not possible to extrapolate from the present data whether PCA might hasten discharge. Further studies of PCA in relation to discharge time are required to answer this question.
